Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Aciont Inc. Allergan Plc Amakem NV Apellis Pharmaceuticals, Inc. Apexigen, Inc. Applied Genetic Technologies Corporatio Avalanche Biotechnologies, Inc. Benitec Biopharma Limited BIOCAD Boehringer Ingelheim GmbH Charlesson LLC. Chong Kun Dang Pharmaceutical Corp. Circadian Technologies Limited Clanotech AB Clearside BioMedical, Inc. Daiichi Sankyo Company, Limited Eleven Biotherapeutics Inc. Exonate Limited F. Hoffmann-La Roche Ltd. Formycon AG GTx, Inc. iCo Therapeutics Inc. Icon Bioscience, Inc. Kala Pharmaceuticals, Inc. Mabion SA Mitotech S.A. Neurotech Pharmaceuticals, Inc. Novartis AG Ocular Therapeutix, Inc. Ohr Pharmaceutical Inc. Ophthotech Corp. Oxford BioMedica Plc PanOptica, Inc. Pfenex Inc. Pfizer Inc. Quark Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. RegenxBio Inc. RXi Pharmaceuticals Corporation Santen Pharmaceutical Co., Ltd. Sanwa Kagaku Kenkyusho Co., Ltd. TRACON Pharmaceuticals, Inc. TWi Pharmaceuticals, Inc. Tyrogenex, Inc. Xbrane Bioscience AB


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###